Masahide Yamamoto

Tokyo, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 72 publications

Successful Treatment with Epcoritamab for Refractory Diffuse Large B-cell Lymphoma in a Dialysis-dependent Patient.

Successful Treatment with Epcoritamab for Refractory Diffuse Large B-cell Lymphoma in a Dialysis-dependent Patient.

Journal: Internal medicine (Tokyo, Japan)

Published: July 20, 2026

Sequential [11C]Acetate and [18F]FDG PET/CT Assessment of Systemic Chronic Active Epstein-Barr Virus Disease: An Exploratory Retrospective Study.

Sequential [11C]Acetate and [18F]FDG PET/CT Assessment of Systemic Chronic Active Epstein-Barr Virus Disease: An Exploratory Retrospective Study.

Journal: Diagnostics (Basel, Switzerland)

Published: May 21, 2026

Treatment-Free Remission and Immune Profiling after Frontline Second-Generation TKI Therapy in CML.

Treatment-Free Remission and Immune Profiling after Frontline Second-Generation TKI Therapy in CML.

Journal: Blood advances

Published: May 05, 2026

Delayed-onset parkinsonism possibly associated with elranatamab treatment for relapsed/refractory multiple myeloma: a case report of a poorly characterized neurological event.

Delayed-onset parkinsonism possibly associated with elranatamab treatment for relapsed/refractory multiple myeloma: a case report of a poorly characterized neurological event.

Journal: Annals of hematology

Published: April 30, 2026

Body Mass Index and Outcomes after CD19 Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory B-Cell Lymphoma: A Nationwide Registry Study.

Body Mass Index and Outcomes after CD19 Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory B-Cell Lymphoma: A Nationwide Registry Study.

Journal: Transplantation and cellular therapy

Published: April 27, 2026

Reattempt of tyrosine kinase inhibitor discontinuation after maintenance therapy with ponatinib in patients with chronic myeloid leukaemia in the chronic phase: Result of the Japan Adult Leukemia Study Group RE-STOP219 study.

Reattempt of tyrosine kinase inhibitor discontinuation after maintenance therapy with ponatinib in patients with chronic myeloid leukaemia in the chronic phase: Result of the Japan Adult Leukemia Study Group RE-STOP219 study.

Journal: British journal of haematology

Published: March 12, 2026

Elranatamab treatment in a refractory multiple myeloma patient on maintenance hemodialysis

Elranatamab treatment in a refractory multiple myeloma patient on maintenance hemodialysis

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology

Published: February 01, 2026

Clinical features and prognostic factors of adult systemic chronic active EBV disease: A retrospective analysis in Japan.

Clinical features and prognostic factors of adult systemic chronic active EBV disease: A retrospective analysis in Japan.

Journal: British journal of haematology

Published: January 01, 2026

Induction chemotherapy with methotrexate, nimustine, and procarbazine for primary CNS lymphoma in the elderly: a retrospective evaluation of safety and efficacy.

Induction chemotherapy with methotrexate, nimustine, and procarbazine for primary CNS lymphoma in the elderly: a retrospective evaluation of safety and efficacy.

Journal: Journal of neuro-oncology

Published: December 12, 2025

Reduced-Dose Bendamustine as a First-Line Treatment of Follicular Lymphoma Is Associated With Poorer Prognosis.

Reduced-Dose Bendamustine as a First-Line Treatment of Follicular Lymphoma Is Associated With Poorer Prognosis.

Journal: Cancer medicine

Published: October 08, 2025

Classical Hodgkin lymphoma associated with immune deficiency and dysregulation exhibits a prognosis similar to sporadic cases but with distinct predictive markers.

Classical Hodgkin lymphoma associated with immune deficiency and dysregulation exhibits a prognosis similar to sporadic cases but with distinct predictive markers.

Journal: Annals of hematology

Published: September 10, 2025

Disease status at CAR T-cell infusion in relapsed or refractory large B-cell lymphoma: prognostic significance for real-world outcomes, irrespective of bridging therapy.

Disease status at CAR T-cell infusion in relapsed or refractory large B-cell lymphoma: prognostic significance for real-world outcomes, irrespective of bridging therapy.

Journal: Bone marrow transplantation

Published: July 26, 2025

Showing 1-12 of 72

Last Updated: 09/26/2026